The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) is leading the development of MDMA and has just reported top-line results from a phase 3 trial of the drug combined with ...

can be prescribed as a treatment for post-traumatic stress disorder (PTSD”. MDMA, which is commonly known as ecstasy, is currently classified as a Schedule I drug under the Controlled Substances ...

First formed in 1986, MAPS has the express purpose of working with the FDA and DEA to make MDMA-assisted talk therapy an approved tool to treat PTSD. Doblin said resigning from the Lykos board ...

One day his psychiatrist handed him a copy of Michael Pollan's "How to Change Your Mind" and told him about the MAPS MDMA trials. "I had a very strong aversion to mind-altering drugs, because by ...

Opinions expressed by Forbes Contributors are their own. A.J. Herrington is freelance writer covering weed news and culture. A California biopharmaceutical company has announced positive results ...

Amy Emerson, the CEO of MAPS, said the organization hopes such approval will “drive additional investment investment into new research in mental health.” MDMA is among a class of psychoactive ...

Maps' chief scientific officer Dr Berra Yazar-Klosinski said MDMA could be legalised and available for prescription by 2023 in the US, and this summer she plans to travel to Europe to begin the ...

Partly, the news has been good. Really good, in fact. MDMA-assisted psychotherapy (MAP) for trauma has been studied by a top-notch group of researchers at several leading universities, and the ...